12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GS-6624: Phase II started

Gilead began a double-blind, U.S. Phase II trial to compare 200 and 700 mg weekly GS-6624 plus gemcitabine vs. gemcitabine plus placebo...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >